Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1302344 | 0.87 | — | — | |
| SCHEMBL1302082 | 0.87 | ADORA1 (0.37) | ALDH1A1TLR7 | |
| SCHEMBL1301858 | 0.74 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL19180241 | 0.70 | TLR7 (0.41) | ALDH1A1POLBTLR8TLR7 | |
| SCHEMBL2043569 | 0.67 | MAPK1 (0.38) | KDM4EALDH1A1GLAPOLBGAA | |
| SCHEMBL1300750 | 0.67 | TLR7 (0.41) | KDM4EALDH1A1HPGDTLR7 | |
| SCHEMBL5739812 | 0.66 | TLR7 (0.63) | TLR8TLR7 | |
| SCHEMBL5337009 | 0.65 | TLR7 (0.37) | TLR8TLR7 | |
| SCHEMBL5337932 | 0.64 | TLR7 (0.35) | TLR8TLR7 | |
| SCHEMBL15545959 | 0.63 | EPHX2 (0.47) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168802-B2 | Ring closing and related methods and intermediates | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-1863770-A2 | RING CLOSING AND RELATED METHODS AND INTERMEDIATES | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006121528-A2 | RING CLOSING AND RELATED METHODS AND INTERMEDIATES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269965-A1 | Ring Closing and Related Methods and Intermediates | CYP11B1, CYP11B2, CYP2F1 | KDM4E 4095/4885ALDH1A1 420/4885GLA 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.